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TKI-resistant GISTAbstract Background: Gastrointestinal stromal tumours (GIST) treated with the tyrosine ki-
nase inhibitor (TKI) imatinib can become resistant when additional mutations in the receptor
tyrosine kinases KIT or PDGFRA block imatinib activity. Mutated KIT requires the molec-
ular chaperone heat-shock protein 90 (HSP90) to maintain stability and activity. Onalespib
(AT13387) is a potent non-ansamycin HSP90 inhibitor. We hypothesised that the combination
of onalespib and imatinib may be safe and effective in managing TKI-resistant GIST.
Patients and methods: In this dose-escalation study, we evaluated the safety and efficacy of
combination once-weekly intravenous onalespib for 3 weeks and daily oral imatinib in 28-
d cycles. Twenty-six patients with TKI-resistant GIST were enrolled into four sequential dose
cohorts of onalespib (dose range, 150e220 mg/m2) and imatinib 400 mg. The relationship be-
tween tumour mutational status (KIT/PDGFRA) and efficacy of treatment was explored.
Results: Common onalespib-related adverse events were diarrhoea (58%), nausea (50%), injec-
tion site events (46%), vomiting (39%), fatigue (27%), and muscle spasms (23%). Overall, 81%
of patients reported more than one onalespib-related gastrointestinal disorder. Nine patients
(35%) had a best response of stable disease, including two patients who had KIT mutations
known to be associated with resistance to imatinib and sunitinib. Disease control at 4 months
was achieved in five patients (19%), and median progression-free survival was 112 d (95% con-
fidence interval 43e165). One patient with PDGFRA-mutant GIST had a partial response for
more than 376 d.
Conclusion: The combination of onalespib plus imatinib was well tolerated but exhibited
limited antitumour activity as dosed in this TKI-resistant GIST patient population.
Trial registration ID: clinicaltrials.gov: NCT01294202
ª 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Gastrointestinal stromal tumours (GIST) are commonly
driven by activating mutations in the KIT or PDGFRA
receptor tyrosine kinases. Although the initial response
rates for newly diagnosed GIST to the tyrosine kinase in-
hibitor (TKI) imatinib can be 50%, most tumours ulti-
mately become resistant [1], commonly through secondary
mutations [2e3] or through alternative pathways [4].
Mutated forms of KIT and PDGFRA are reliant on
the heat-shock protein 90 (HSP90) chaperone for their
functional stabilisation [5e6]. Inhibition of HSP90
function causes degradation of KIT in vitro and inhibits
tumour growth in GIST models [7e11]. In a phase 1
trial of the geldanamycin analogue HSP90 inhibitor IPI-
504, stable disease (assessed by RECIST 1.0) was
observed in 70% of patients with metastatic and/or
unresectable GIST (n Z 37), with one partial response;
metabolic partial responses were observed in 38% of
these patients [12]. In a phase 2 trial of the non-
ansamycin HSP90 inhibitor BIIB021, stable disease
(assessed by RECIST 1.0) was observed in 43% of pa-
tients with GIST refractory to imatinib and sunitinib,
with a 22% metabolic partial response rate [13].
Onalespib is a potent non-ansamycin HSP90 inhibitor
that shows activity in many preclinical models, including
imatinib-sensitive and -resistant GIST [11,14e15]. Pre-
liminary antitumour activity was observed in patients with
GIST in a phase 1 study of onalespib monotherapy [16].
The combination of onalespib with imatinib was welltolerated inmice andwas shown to inhibit tumour growth
in a TKI-resistant model [11]. Here, we describe a phase 1
study investigating the safety and efficacy of onalespib in
combinationwith imatinib inpatientswithGIST. Imatinib
was given in combinationwith onalespib for the possibility
that a subpopulation of tumour cells may still be sensitive
to imatinib [4,17] and that combining partial kinase inhi-
bition with reduced KIT levels would lead to a synergistic
or additive decrease in oncogenic KIT signalling.
2. Patients and methods
2.1. Patient selection
Patients included in the study were 18 years of age,
ECOG performance status 0 or 1, with unresectable
and/or metastatic GIST with objective progression of
disease following previous treatment with a maximum of
three TKIs, including imatinib. The trial was carried out
in accordance with the Declaration of Helsinki. All pa-
tients provided written informed consent and the study
was approved by local institutional review boards.
2.2. Study objectives
The primary objective of this study was to evaluate the
antitumour effects of onalespib in combination with
imatinib. Secondary objectives were to evaluate the
safety, maximum tolerated dose (MTD), and pharma-
cokinetic (PK) profile of onalespib plus imatinib and to
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mutational status.2.3. Study design and treatment administration
A standard 3þ3 dose-escalation design was used to
define the MTD of intravenous (i.v.) onalespib admin-
istered once weekly for 3 weeks of each 4-week cycle in
combination with daily oral imatinib (400 mg).
Four sequential dose levels were tested following
safety monitoring committee (SMC) recommendations:
180 mg/m2 (Cohort 1), 150 mg/m2 (Cohort 2), 180 mg/
m2 (Cohort 3), and 220 mg/m2 (Cohort 4). Patients who
exhibited evidence of clinical benefit and continued to
meet the eligibility criteria were allowed to remain on
study until they withdrew consent or experienced disease
progression or until the study was terminated.
Adverse event (AE) severity grades were determined
usingNCI-CTCAEv4.03. Standard criteria were used for
dose-limiting toxicities (DLTs), with the exception of
nausea, vomiting, or diarrhoea in the absence of appro-
priate prophylaxis; in addition, the omission ofmore than
one dose during the first cycle of treatment because of
toxicity related to onalespib was considered a DLT.
Tumour images (computed tomography or magnetic
resonance imaging scans) were evaluated using RECIST
1.1 [18]. The primary end-point was disease control rate
(i.e. the proportion of subjects who exhibited reduction or
stabilisation of tumour size) at 4months per RECIST 1.1.
Serum onalespib concentrations and PK parameters
were measured as described previously [16]. Tumour
KIT and PDGFRA genotypes were determined from
historical records or from new or archived tumour bi-
opsies, as previously described [19].
This study is registered in the clinicaltrials.gov under
the identifier NCT01294202.3. Results
3.1. Patient disposition and characteristics
Twenty-six patients were enrolled in the study between
May 2011 and April 2013. All patients (n Z 26) had
received prior TKI therapy for GIST. Most patients
(n Z 24, 92%) had undergone prior surgical treatment
and three patients (12%) had received radiotherapy.
Patient demographics and baseline characteristics are
summarised in Table 1.
The median number of onalespib cycles administered
per patient was 2 (range 1e14 cycles); three patients
(11.5%) received six or more cycles. Overall, 11 patients
(42%) stopped treatment due to disease progression and
12 (46%) withdrew for personal reasons or as a result of
an AE, including events that were primarily the result of
GIST progression. One patient (4%) was withdrawn
from study treatment due to protocol non-compliance.For two patients (8%), the primary reason for with-
drawal from study was death due to disease progression
or complications of disease progression. Patient
screening, enrolment, and disposition are summarised in
Fig. 1.
3.2. Dose-limiting toxicities
Patients were assessed for DLTs during Cycle 1. Two
renal events (Grade II increased creatinine in one patient
and Grade IV acute renal failure in another) in Cohort 1
(180 mg/m2) were classified as DLTs. Both patients were
taking antihypertension medications; one had slightly
elevated serum creatinine at baseline (1.6e1.9 mg/dl,
normal range 0.7e1.3) and the other had a history of a
kidney tumour, renal injury, and ongoing neph-
rolithiasis. Because of these events, the SMC recom-
mended de-escalating onalespib to 150 mg/m2 for
Cohort 2 and amending the protocol eligibility criteria
to exclude patients who had elevated serum creatinine or
reduced estimated creatinine clearance. After the pro-
tocol eligibility criteria were amended, no further
treatment-related AEs indicative of a decline in renal
function greater than Grade I were reported.
Two non-renal DLTs also occurred. In Cohort 3
(180 mg/m2), Grade III subcapsular hepatic haemor-
rhage led to discontinuation of study treatment in a
patient with pre-existing coagulopathy and extensive
hepatic metastases. In Cohort 4 (220 mg/m2), Grade IV
increased blood creatine phosphokinase (CPK) and was
reported in one patient. The study was terminated early,
without identifying an MTD, for several non-safety-
related reasons, including subject recruitment chal-
lenges, limited antitumour activity, and increasing
availability of alternative treatment options.
3.3. Safety
The most common AEs (occurring in 20% of patients)
considered to be related to onalespib were diarrhoea
(58%), nausea (50%), injection site events (46%), vom-
iting (39%), fatigue (27%), and muscle spasms (23%)
(Table 2). Overall, 81% of patients reported one or more
onalespib-related gastrointestinal (GI) disorders; other
GI disorders reported in 5% of patients included dry
mouth, abdominal distention, and dyspepsia. AEs re-
ported as “ongoing” at the time of last assessment in
10% of subjects were diarrhoea (26.9%), fatigue
(23.1%), muscle spasms (11.5%), anaemia (11.5%),
hypokalaemia (11.5%), and decreased appetite (11.5%).
For more information on injection site events, visual
disturbances (23%), and systemic infusion reactions
(19%), see Supplementary data.
The most common imatinib-related AEs (in 20% of
patients) were diarrhoea (54%), nausea (50%), vomiting
(39%), fatigue (27%), and muscle spasms (23%). Seven
patients (27%) had one or more Grade III or IV AEs
Fig. 1. Screening, enrolment, and disposition flow chart.
Table 1
Patients’ baseline characteristics.
Demographic characteristicsa Cohort 1,
180 mg/m2 (N Z 7)
Cohort 2,
150 mg/m2 (N Z 7)
Cohort 3,
180 mg/m2 (N Z 6)
Cohort 4,
220 mg/m2 (N Z 6)
Total (N Z 26)
Age (years)
Mean  SD 61.0  16.2 60.0  4.2 56.0  8.0 58.8  10.3 59.1  10.2
Median 64.0 60.0 56.0 53.0 58.5
Sex
Females 4 (57.1) 1 (14.3) 0 2 (33.3) 7 (26.9)
Males 3 (42.9) 6 (85.7) 6 (100.0) 4 (66.7) 19 (73.1)
ECOG performance status
0 4 (57.1) 5 (71.4) 0 5 (83.3) 14 (53.8)
1 3 (42.9) 2 (28.6) 6 (100.0) 1 (16.7) 12 (46.2)
Previous therapies
Surgery 6 (85.7) 7 (100.0) 5 (83.3) 6 (100.0) 24 (92.3)
Chemotherapy 0 0 0 0 0
Radiotherapy 0 2 (28.6) 0 1 (16.7) 3 (11.5)
TKI therapy 7 (100.0) 7 (100.0) 6 (100.0) 6 (100.0) 26 (100.0)
Other therapies 0 0 0 0 0
Number of previous TKIs receivedb
None 0 0 0 0 0
1 1 (14.3) 0 1 (16.6) 0 2 (76.3)
2 4 (57.1) 4 (57.1) 3 (50.0) 3 (50.0) 14 (53.4)
3 2 (28.6) 3 (42.3) 2 (33.3) 3 (50.0) 10 (38.5)
ECOG Z Eastern Cooperative Oncology Group; SD Z standard deviation; TKI Z tyrosine kinase inhibitor.
a Unless noted otherwise, the values show the numbers and percentages (in parentheses) of patients.
b The number of different TKI agents that were previously received, not the number of TKI regimens received.
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study was similar to that reported in the prescribing
information.
One patient died on study (31 d after the last infusion
of onalespib in Cycle 5) as a result of a serious AE
considered unrelated to study treatment (renal failure).Five patients died as a result of disease progression
within 30 d after the last dose of onalespib or imatinib.
The majority of onalespib-related AEs were Grade I
or II. Eight patients (31%) were reported to have one or
more Grade III or IV AEs related to onalespib,
including the following: anaemia (n Z 4, 15%);
increased blood CPK (n Z 2, 8%); increased aspartate
Table 2
Summary of AEs related to onalespib treatment occurring in 10% of patients, n (%).
AEa MedDRA system
organ class preferred
term/grouped term
Cohort 1,
180 mg/m2
(N Z 7)
Cohort 2,
150 mg/m2
(N Z 7)
Cohort 3,
180 mg/m2
(N Z 6)
Cohort 4,
220 mg/m2
(N Z 6)
Total
(N Z 26)
CTCAE
Grade IIIþIV AEs
GI disorders 6 (85.7) 5 (71.4) 5 (83.3) 5 (83.3) 21 (80.8)
Diarrhoea 5 (71.4) 5 (71.4) 2 (33.3) 3 (50.0) 15 (57.7) 1 (3.8)
Nausea 3 (42.9) 4 (57.1) 2 (33.3) 4 (66.7) 13 (50.0) 0
Vomiting 3 (42.9) 2 (28.6) 4 (66.7) 1 (16.7) 10 (38.5) 0
Dry mouth 0 2 (28.6) 1 (16.7) 0 3 (11.5) 0
General disorders and
administration site conditions
5 (71.4) 5 (71.4) 3 (50.0) 5 (83.3) 18 (69.2)
Injection site eventsb 4 (57.1) 4 (57.1) 1 (16.7) 3 (50.0) 12 (46.2) 0
Fatigue 0 2 (28.6) 3 (50.0) 2 (33.3) 7 (26.9) 0
Systemic infusion reactionb 1 (14.3) 1 (14.3) 1 (16.7) 2 (33.3) 5 (19.2) 0
Oedema peripheral 1 (14.3) 0 1 (16.7) 1 (16.7) 3 (11.5) 0
Investigations 3 (42.9) 1 (14.3) 3 (50.0) 3 (50.0) 10 (38.5)
ECG QT prolonged 1 (14.3) 1 (14.3) 0 2 (33.3) 4 (15.4) 0
AST increased 1 (14.3) 0 2 (33.3) 0 3 (11.5) 1 (3.8)
Metabolism and nutrition disorders 3 (42.9) 1 (14.3) 2 (33.3) 3 (50.0) 9 (34.6)
Hypokalaemia 2 (28.6) 1 (14.3) 1 (16.7) 1 (16.7) 5 (19.2) 0
Decreased appetite 1 (14.3) 0 0 3 (50.0) 4 (15.4) 1 (3.8)
Hypomagnesaemia 1 (14.3) 1 (14.3) 1 (16.7) 1 (16.7) 4 (15.4) 0
Musculoskeletal and
connective tissue disorders
2 (28.6) 2 (28.6) 1 (16.7) 4 (66.7) 9 (34.6)
Muscle spasms 2 (28.6) 1 (14.3) 1 (16.7) 2 (33.3) 6 (23.1) 0
Psychiatric disorders 0 2 (28.6) 3 (50.0) 2 (33.3) 7 (26.9)
Insomnia 0 2 (28.6) 2 (33.3) 1 (16.7) 5 (19.2) 0
Blood and lymphatic system disorders 2 (28.6) 0 2 (33.3) 2 (33.3) 6 (23.1)
Anaemia 2 (28.6) 0 1 (16.7) 2 (33.3) 5 (19.2) 4 (15.4)
Nervous system disorders 2 (28.6) 2 (28.6) 1 (16.7) 1 (16.7) 6 (23.1)
Headache 1 (14.3) 2 (28.6) 1 (16.7) 1 (16.7) 5 (19.2) 0
Eye disorders 2 (28.6) 2 (28.6) 1 (16.7) 1 (16.7) 6 (23.1)
Visual disturbancesb 2 (28.6) 1 (14.3) 0 0 3 (11.5) 0
AE Z adverse event; AST Z aspartate transaminase; ECG QT Z electrocardiogram QT interval; GI Z gastrointestinal; MedDRA Z Medical
Dictionary for Regulatory Activities.
a AEs considered possibly, probably, or definitely related to onalespib treatment.
b In this study, the group term ‘injection site events’ included the following specific AE preferred terms: infusion site extravasation, infusion site
pain, injection site pain, and injection site reaction. The group term ‘systemic infusion reaction’ included flushing, hyperhidrosis, and infusion-
related reactions, if they were definitely or possibly related to onalespib and occurred within 24 h of a dose. The group term ‘visual disturbances’
included photopsia, vision blurred, visual impairment, and vitreous floaters.
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bilirubin (n Z 1 each); and decreased neutrophil count,
coagulopathy, diarrhoea, abdominal pain, dehydration,
decreased appetite, hyponatremia, myalgia, renal failure
acute, subcapsular hepatic haemorrhage, and hyperten-
sion (n Z 1 each).
Onalespib-related AEs leading to permanent discon-
tinuation of study treatment were reported in four pa-
tients (15%): dehydration and acute renal failure (both
in one patient), hepatic haemorrhage (in one patient),
blood CPK increased (in one patient), and blood
creatinine increased (in one patient). Additionally, in
nine patients (35%), one or more doses of onalespib
were omitted, interrupted, or reduced, predominantly
due to AEs (although not all attributable to onalespib).
Infusion interruption in three patients and dose reduc-
tion in one patient were due to injection site events.
Overall, no clinically significant or treatment-related
trends were observed in clinical laboratory assessments.
The most common laboratory parameters reported astreatment-related AEs were anaemia (five patients, four
cases Grade III), hypokalaemia (five patients, all Grade
I or II), and hypomagnesaemia (four patients, all Grade
I or II). Six subjects (23%) had one or more onalespib-
related laboratory AEs that were ongoing at the end of
the study, all of which were Grade I or II; most were
considered to be related to imatinib. For further dis-
cussion of laboratory values reported as treatment-
related AEs, see Supplementary data and Table S1.
Effects on liver function were mild and unrelated to
onalespib, with the exception of one patient in Cohort 3
who had Grade IV AEs of elevated ALT (23 upper
limit of normal [ULN]) and AST (33 ULN) on study
day 9. These events were likely related to ongoing Grade
III subcapsular hepatic haemorrhage, which resolved
with sequelae in 84 d.
Central analysis of cardiac repolarisation (Fridericia-
corrected QT interval [QTcF] duration) in this small
sample revealed no clinically significant prolongation.
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The exposure of onalespib increased in a dose-
proportional manner over the dosing range of
150e220 mg/m2 per dose following once-weekly i.v.
infusion (see Supplementary data Table S2, and Fig. S1)
and is consistent with the experience from the phase I
single-agent study [16]. There was no evidence of an
effect of imatinib on onalespib elimination.
3.5. Antitumour activity
Based on the investigators’ response assessments, dis-
ease control at 4 months was achieved in five patients
(19.2%, 95% CI 6.6e39.4) and at 6 months in three
patients (11.5%, 95% CI 2.4e30.2). Median progression-
free survival (PFS) was 112 d (95% CI 43e165) and
median overall survival was 184 d (lower 95% CI 141,
upper 95% CI unknown).
One patient (3.8%, 95% CI 0.1e19.6) exhibited a
partial response that was ongoing when the patient
withdrew from the study after 376 d. Nine patients
(34.6%) had a best response of stable disease, which in
one case lasted for approximately 10 months (303 d).
Nine patients (34.6%) had disease progression as best
response, and seven (26.9%) were not evaluable. For
patients with measurable disease, each patient’s best
percentage change in tumour size is shown in Fig. 2.Fig. 2. Best percentage change in tumour size from baseline, based on
plot represents, for a given patient, either (a) the largest percentage
shrinkage) or (b) the smallest percentage ‘increase’ in tumour size from
largest percentage decrease in tumour size was observed in a patient wh
to have an objective (partial) response. One patient received ten cycles
these patients, the best overall response was stable disease. All other p3.6. Relationship of antitumour activity to KIT and
PDGFRA mutational status
The KIT and PDGFRA mutational status of the target
tumour was determined for 23 of the 26 patients. Bi-
opsies for genotyping were obtained from two patients
during the study screening process. For the remainder of
the patients (>90%), mutation data were obtained either
from patient records or from genotyping performed on
archived biopsies that had been obtained up to 12.5
years (median, w5 years) prior to the subjects’ entry
into the study.
Fourteen of 23 patients (62%) had tumours with only
primary mutations in KIT exons 9 or 11 (data not
shown). Six of these 14 patients (43%) had a best
response of stable disease (range 94e182 d); five subjects
were non-evaluable and three subjects had progressive
disease. The majority (>75%) of the biopsies were
collected 2 years prior to first dose of onalespib; so,
these patients could have acquired additional mutations
prior to the start of the study.
Five of 23 patients (22%) had tumours with KIT
mutations associated with imatinib or sunitinib resis-
tance [4,20]; two of these five patients had a best
response of stable disease (89 and 165 d, respectively)
(Table 3). One of 23 patients (4%) had a tumour with a
deletion in exon 18 of the activation loop of PDGRFA
(DIMH 842-845), which is associated with sensitivity totarget lesion assessments by investigator. Each bar in the waterfall
‘decrease’ in tumour size from baseline (if there was any tumour
baseline (if there was no tumour shrinkage), at any time point. The
o received 14 cycles of study treatment; this patient was determined
of study treatment and one patient received six cycles; for both of
atients received five or less cycles.
Table 3
KIT or PDGFRA mutation status of GIST and best response to combination therapy.
Patient Type of KIT or PDGFRA mutation, if any Time elapsed
since tumour
biopsied for
genotyping
Previous TKI therapy(ies) Overall disease assessment:
best response (duration)
KIT mutations associated with resistance to imatinib or sunitinib
107201 Exon 13 V654A 4 years Regorafenib, imatinib, sunitinib, Disease progression
108305 Exon 17 D816E 4 months Imatinib, sunitinib Stable disease (165 d)
107401 Exon 13 V654A 3.5 years Imatinib, sunitinib, sorafenib Disease progression
105404 Exon 17 D820E <1 month
(new/current biopsy)
Imatinib, sunitinib, sorafenib Disease progression
107405 Exon 17 ND 819 and 820, exon 13 V654A 9 months Imatinib, sunitinib Stable disease (89 d)
PDGFRA mutations
106102 Exon 18 deletion DIMH 842-845 5.5 years Imatinib, sunitinib Partial response (376 d)a
Wild-type for KIT and PDGFRA
102105 None 8.5 years Imatinib, sunitinib, nilotinib Not assessed
103303 None 4.5 years Imatinib, sunitinib Stable disease (303 d)
103406 None 8 months Imatinib, sunitinib Disease progression
GIST Z gastrointestinal stromal tumours; TKI Z tyrosine kinase inhibitor.
Notes: The 14 patients whose GIST had only primary KIT mutations at the time of biopsy were not included. Six of the 14 patients had a best
response of stable disease; the other patients either were not assessed or had disease progression. All five patients who had KIT mutations
associated with resistance to imatinib or sunitinib also had a primary mutation in KIT exon 11.
a Ongoing at last patient contact, when patient withdrew consent.
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partial response to combination therapy in this study.
Finally, one of the three patients who had tumours
without identifiable mutations in KIT or PDGFRA had
stable disease for 303 d.
4. Discussion
Treatment with the combination of onalespib plus
imatinib was generally well tolerated, and the safety
profile was consistent with published reports of patients
treated with onalespib and imatinib as monotherapies.
The MTD of onalespib in combination therapy was not
defined, as the study was terminated early due to
insufficient efficacy and other non-safety-related reasons
after Cohort 4 (220 mg/m2) was complete. For com-
parison, 260 mg/m2 was the recommended phase 2
dose for onalespib monotherapy using a similar dosing
regimen (once-weekly i.v. administration [16]).
Antitumour activity was limited with study drugs as
dosed in this study, with a single partial response (3.8%,
95% CI 0.1e19.6). The median PFS in this study (w3.5
months) compared favourably with the median PFS (1.8
months) recently reported in a study of patients with
TKI-resistant metastatic GIST who resumed treatment
with imatinib monotherapy [17]. While the results may
be viewed as encouraging, it is not possible to make a
definitive conclusion about efficacy from this small
exploratory study. The occurrence of stable disease in
two patients with KIT mutations associated with resis-
tance to imatinib or sunitinib and prolonged disease
stabilisation in one of three patients with no identifiable
activating mutations is consistent with a potentially
better outcome than seen with other investigationalagents in a proportion of patients with GIST with bio-
logically unfavorable characteristics (reviewed in 20).
Interpretation of the genotyping results is confounded
by the fact that the majority of the tumour biopsy
samples were collected several years prior to the initia-
tion of study dosing with onalespib plus imatinib.
5. Conclusions
The MTD of onalespib in combination with standard
dose imatinib was not reached, as the study was closed
early. The highest dose of onalespib that was safely
administered in combination with imatinib in patients
with baseline normal renal function was 220 mg/m2 once
weekly for 3 weeks of every 4-week cycle. Treatment
with the combination of onalespib and imatinib was well
tolerated, and treatment-related toxicities were consis-
tent with those previously reported following single-
agent therapy with either imatinib or onalespib. The
appearance of renal toxicity following a relatively low
dose of onalespib was unexpected, but may have been
due to pre-existing renal impairment or vascular disease.
In this exploratory dose-finding study, combination
therapy achieved limited efficacy in TKI-resistant GIST.
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